Science for cure
Personalised cancer therapy
Providing hope for cancer patients: Our vision for a better future
Imagine a world where cancer patients who lack effective treatment options can be cured. With our innovative cell therapy product, currently in clinical trial, we are bringing this vision closer to reality. Our unique approach trains the patient’s own immune cells to target and eliminate cancer cells, providing a tailor-made treatment for each patient.
The story of Neogap
Neogap Therapeutics is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology.
Discover Neogap's innovative pTTL cell therapy and patented technology
Our pTTL cell therapy product, which targets neoantigens, is just one example of our novel technology at Neogap. Manufactured using our proprietary PIOR® and patented EpiTCer® technologies, pTTL consists of T cells targeting neoantigens using immune cells from cancer patients as starting material.
The growing colorectal cancer therapeutics market
Neogap is dedicated to advancing the field of personalised immunotherapy to combat cancer, starting with our focus on colorectal cancer. Our experienced team of professionals from academia and the pharmaceutical industry is committed to developing innovative solutions that are at the forefront of cancer research. Our pTTL cell therapy product is a testament to this dedication.
We also believe in the power of collaboration and are open to partnering with organisations that share our vision for advancing the field of personalised immunotherapy for cancer treatment.
Latest news from Neogap
Neogap launches collaboration with Weill Cornell Medicine through Vinnova-funded project
Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has been awarded a SEK 1 million grant from Vinnova, Sweden’s innovation agency, to initiate a collaborative project with Weill Cornell Medicine in New York, U.S. The initiative will explore pathways for conducting future clinical studies in the United States.
ILCO Visits Neogap: Patient Perspectives on Clinical Trials and pTTL Cell Therapy
The patient organisation ILCO joined us at Neogap to share their views on participation in clinical trials in Sweden and to learn more about our innovative pTTL cell therapy. The meeting was highly insightful and provided us with valuable new perspectives.
Neogap strengthens global IP position with Chinese patent for T cell expansion method
Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has been granted a Chinese patent for its method of expanding tumour-specific T cells – a key component of the company’s therapeutic approach. The grant strengthens Neogap’s international IP position and supports its long-term strategy to protect and advance its proprietary technologies globally.